Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cumulative dose

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    780 result(s) found for: Cumulative dose. Displaying page 2 of 39.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-000451-13 Sponsor Protocol Number: 1201 Start Date*: 2012-10-16
    Sponsor Name:Transplant Institute, Sahlgrenska University Hospital
    Full Title: A controlled randomized, open-label, multi-centre study evaluating if a steroid-free immunosuppressive protocol, based on single dose ATG-induction, low tacrolimus-dose and therapeutic drug monitor...
    Medical condition: Prophylaxis of rejection in kidney allograft recipients (by immunosuppression)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10050436 Prophylaxis against renal transplant rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-005126-35 Sponsor Protocol Number: GBG86-DESIREE Start Date*: 2015-06-03
    Sponsor Name:GBG Forschungs GmbH
    Full Title: A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer
    Medical condition: Advance Breast cancer under endocrine treatment
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    21.1 100000004864 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000774-23 Sponsor Protocol Number: CCD-0701-PR-0020 Start Date*: 2007-05-10
    Sponsor Name:Chiesi Farmaceutici S.p.A
    Full Title: EVALUATION OF CARDIAC SAFETY, TOLERABILITY AND EFFICACY OF CUMULATIVE DOSES OF CHF5188 pMDI (FIXED COMBINATION BUDESONIDE/CARMOTEROL 200/1 µg) COMPARED TO SAME CUMULATIVE DOSES OF CARMOTEROL pMDI A...
    Medical condition: Stable persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-003713-28 Sponsor Protocol Number: 2014-08 Start Date*: 2014-11-06
    Sponsor Name:Univeritetssjukhuset Örebro [...]
    1. Univeritetssjukhuset Örebro
    2. Universitetssjukhuset Örebro
    Full Title: What is the post operative opioid-reducing effect of the beta-receptor-agonist esmolol when administered during laparoscopic gastric by-pass surgery? Comparison between standard anesthesia and anes...
    Medical condition: Effect on post operative opioid consumption after laparoscopic gastric by-pass in obese
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004176-35 Sponsor Protocol Number: AH-09-10 Start Date*: 2015-06-26
    Sponsor Name:Pfizer
    Full Title: Evaluation Of The Efficacy Of A Novel Ibuprofen Formulation In The Treatment Of Post Surgical Dental Pain: Study I
    Medical condition: Post Surgical Dental Pain
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-005406-96 Sponsor Protocol Number: AB20006 Start Date*: 2022-10-07
    Sponsor Name:AB Science
    Full Title: A 24-week, multicenter, randomized, double blind, placebo-controlled, dose-range finding phase II study to compare efficacy and safety of oral masitinib to placebo in treatment of patients with sev...
    Medical condition: severe mast cell activation syndrome (MCAS) with handicap unresponsive to optimal symptomatic treatment
    Disease: Version SOC Term Classification Code Term Level
    20.1 10005329 - Blood and lymphatic system disorders 10075217 Mast cell activation syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-004134-16 Sponsor Protocol Number: Start Date*: 2008-02-11
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: Effectiveness and Safety of Pregabalin (Lyrica) in treatment of in-patients with ethanol withdrawal syndrom
    Medical condition: Patients with alcohol dependence in withdrawal states.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005339-56 Sponsor Protocol Number: CQGE031G12301 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma AG
    Full Title: A 52 week, multi-center, randomized, double-blind placebo-controlled study to assess the clinical efficacy and safety of ligelizumab (QGE031) in decreasing the sensitivity to peanuts in patients wi...
    Medical condition: Allergy, Peanut
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10034202 Peanut allergy LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) ES (Ongoing) DE (Prematurely Ended) IT (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004244-37 Sponsor Protocol Number: KF7013-04 Start Date*: 2018-08-16
    Sponsor Name:Grünenthal GmbH
    Full Title: Placebo-controlled efficacy and safety trial of intravenous neridronic acid in subjects with complex regional pain syndrome (CRPS)
    Medical condition: Complex Regional Pain Syndrome (CRPS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10064334 Complex regional pain syndrome Type I LLT
    20.1 100000004852 10064335 Complex regional pain syndrome Type II LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2005-002570-30 Sponsor Protocol Number: EFC5505 Start Date*: 2005-12-07
    Sponsor Name:Sanofi-Synthelabo Recherche
    Full Title: A multicenter, randomized double-blind placebo controlled Phase III study of the efficacy of xaliproden in preventing the neurotoxicity of oxaliplatin in first-line treatment of patients with metas...
    Medical condition: Patients with metastatic colorectal cancer treated with oxaliplatin/5-FU/LV; at risk of cumulative peripheral sensory neuropathy (PSN) relative to cumulative dose of oxaliplatin.
    Disease: Version SOC Term Classification Code Term Level
    8 10034620 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) ES (Completed) PT (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-002885-34 Sponsor Protocol Number: CHIP-AML22/Master Start Date*: 2023-03-17
    Sponsor Name:Princess Máxima Center
    Full Title: CHIP-AML22 Master protocol: An open label complex clinical trial in newly diagnosed pediatric de novo AML patients – a study by the NOPHO-DB-SHIP consortium
    Medical condition: Acute Myeloid Leukemia
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002333-19 Sponsor Protocol Number: OMS112831 Start Date*: 2011-11-29
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A Randomized, Double-blind, Placebo controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months’ administration of Ofatumumab in Subjects with Relapsing-...
    Medical condition: Relapsing-Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029205 - Nervous system disorders 10070716 Multiple sclerosis pseudo relapse LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) NL (Completed) DK (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-000725-18 Sponsor Protocol Number: MAB110123 Start Date*: 2008-04-03
    Sponsor Name:GlaxoSmithKline Reaseach & Development
    Full Title: A randomised, double-blind, crossover study to investigate the bronchodilatation post-inhalation of GSK961081 alone and with the addition of cumulative doses of short acting bronchodilators (salbut...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-001886-35 Sponsor Protocol Number: RHMCRI0399 Start Date*: 2020-05-15
    Sponsor Name:University Hospital Southampton NHS Foundation Trust
    Full Title: A clinical trial of nebulized surfactant for the Treatment of moderate to severe COVID-19 in adults
    Medical condition: COVID-19 infection in patients requiring endotrachael intubation
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-005004-26 Sponsor Protocol Number: ARC010 Start Date*: 2017-04-12
    Sponsor Name:Aimmune Therapeutics, Inc.
    Full Title: AR101 TRIAL IN EUROPE MEASURING ORAL IMMUNOTHERAPY SUCCESS IN PEANUT ALLERGIC CHILDREN (ARTEMIS)
    Medical condition: Peanut Allergy
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) DE (Completed) ES (Completed) SE (Completed) IE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-004744-32 Sponsor Protocol Number: 04-SAM-01/BS554 Start Date*: 2006-01-25
    Sponsor Name:Merck Generics UK Ltd.
    Full Title: A CUMULATIVE DOSE RESPONSE STUDY TO EVALUATE THE THERAPEUTIC EQUIVALENCE OF A NEW SALMETEROL INHALATION AEROSOL CONTAINING A REPLACEMENT HFA PROPELLANT IN A PRESSURISED METERED DOSE INHALER AND EX...
    Medical condition: asthma bronchiale
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003702-41 Sponsor Protocol Number: IDR-OM-02 Start Date*: 2018-07-03
    Sponsor Name:Soligenix UK Limited
    Full Title: A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated With Concomitant Chemoradiation for...
    Medical condition: Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) FR (Ongoing) ES (Completed) HU (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001691-39 Sponsor Protocol Number: UKM17_0023 Start Date*: 2019-07-16
    Sponsor Name:University Hospital Münster
    Full Title: LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma
    Medical condition: Lymphoblastic lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10065923 Lymphoblastic lymphoma LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) DE (Ongoing) DK (Trial now transitioned) IE (Completed) NO (Trial now transitioned) FI (Trial now transitioned) AT (Trial now transitioned) CZ (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) NL (Ongoing) SK (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-005001-39 Sponsor Protocol Number: 4658-us-202 Start Date*: 2017-03-16
    Sponsor Name:Sarepta Therapeutics, Inc.
    Full Title: Open-Label, Multiple-Dose, Efficacy, Safety, and Tolerability Study of Eteplirsen in Subjects with Duchenne Muscular Dystrophy who Participated in Study 4658-us-201
    Medical condition: Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
    Disease: Version SOC Term Classification Code Term Level
    19.1 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Under 18 Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-004383-19 Sponsor Protocol Number: GORTEC_2017-01 Start Date*: 2017-09-07
    Sponsor Name:GORTEC
    Full Title: A Phase III randomized trial of avelumab-cetuximab-Radiotherapy versus standards of care in locally advanced squamous cell carcinoma of the head and neck
    Medical condition: Squamous cell carcinoma, previously untreated Stage III, stage IVa (i.e. operable, but not operated) or IVb (non resectable) Oral cavity, oropharynx, hypopharynx or larynx
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 25 01:31:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA